Adaptimmune Therapeutics (ADAP) Institutional Ownership $0.06 0.00 (-1.71%) As of 03:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Adaptimmune Therapeutics (NASDAQ:ADAP)CurrentInstitutional OwnershipPercentage31.37%Number ofInstitutional Buyers(last 12 months)17TotalInstitutional Inflows(last 12 months)$25.21MNumber ofInstitutional Sellers(last 12 months)9TotalInstitutional Outflows(last 12 months)$5.79M Get ADAP Insider Trade Alerts Want to know when executives and insiders are buying or selling Adaptimmune Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ADAP Institutional Buying and Selling by Quarter Adaptimmune Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/14/2025 MPM Bioimpact LLC4,411,821$1.06M0.2%-9.9%1.665% 8/14/2025 MPM Asset Management LLC4,809,677$1.15M2.7%-9.9%1.815% 8/13/2025 Two Seas Capital LP22,580,701$5.41M0.1%+10.0%8.519% 8/11/2025 Empirical Finance LLC800,000$192K0.0%N/A0.302% 7/14/2025 Clear Harbor Asset Management LLC145,400$35K0.0%-39.6%0.055% 5/21/2025 Acadian Asset Management LLC2,218,215$424K0.0%+334.8%0.862% 5/16/2025 Two Seas Capital LP20,529,685$4.04M0.1%+38.4%7.981% 5/15/2025 MPM Bioimpact LLC4,894,344$964K0.2%-4.0%1.903% 5/15/2025 MPM Asset Management LLC5,335,715$1.05M1.5%-4.0%2.074% 5/15/2025 Long Focus Capital Management LLC23,756,687$4.68M0.2%+15.9%9.236% Get the Latest News and Ratings for ADAP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 4/10/2025 Key Client Fiduciary Advisors LLC150,150$30K0.0%-41.2%0.058% 2/18/2025 Two Seas Capital LP14,835,146$7.99M0.6%N/A5.798% 2/17/2025 Two Sigma Investments LP76,347$41K0.0%+33.5%0.030% 2/17/2025 Two Sigma Advisers LP70,735$38K0.0%+492.0%0.028% 2/17/2025 Bank of America Corp DE2,862,330$1.54M0.0%-38.5%1.119% 2/14/2025 Jane Street Group LLC326,937$176K0.0%+87.7%0.128% 2/14/2025 Two Seas Capital LP14,835,146$7.99M0.7%N/A5.798% 2/14/2025 Long Focus Capital Management LLC20,494,393$11.04M0.4%+54.1%8.009% 2/14/2025 Rock Springs Capital Management LP2,483,468$1.34M0.1%+2.4%0.971% 2/13/2025 Renaissance Technologies LLC2,526,524$1.36M0.0%+52.5%0.987% 2/13/2025 Invesco Ltd.63,335$34K0.0%+82.0%0.025% 2/12/2025 JPMorgan Chase & Co.916,941$494K0.0%-12.3%0.358% 2/11/2025 LPL Financial LLC183,479$99K0.0%+106.5%0.072% 2/11/2025 Virtu Financial LLC122,696$66K0.0%+21.5%0.048% 1/31/2025 Baillie Gifford & Co.11,819,095$6.37M0.0%-29.5%4.619% 11/20/2024 Virtu Financial LLC101,008$96K0.0%+27.5%0.039% 11/15/2024 Jane Street Group LLC174,157$166K0.0%+130.4%0.068% 11/15/2024 Matrix Capital Management Company LP37,681,515$35.81M1.7%-3.3%14.734% 11/14/2024 PFM Health Sciences LP10,000,787$9.51M0.5%-4.9%3.911% 11/13/2024 FMR LLC1,740,900$1.66M0.0%+3.0%0.681% 11/5/2024 Baillie Gifford & Co.16,775,860$15.94M0.0%+10.7%6.560% 11/5/2024 GSA Capital Partners LLP99,662$95K0.0%N/A0.039% 10/29/2024 Fullcircle Wealth LLC35,000$33K0.0%N/A0.014% 10/16/2024 Vontobel Holding Ltd.43,000$41K0.0%+230.8%0.017% 8/15/2024 Long Focus Capital Management LLC12,346,417$12.04M0.5%+15.6%5.002% 8/14/2024 Marshall Wace LLP144,880$141K0.0%-43.0%0.059% 8/9/2024 Renaissance Technologies LLC1,786,341$1.74M0.0%+28.3%0.724% 7/25/2024 Baillie Gifford & Co.15,149,203$14.77M0.0%-4.6%6.138% 5/15/2024 Baker BROS. Advisors LP10,787,022$17.04M0.2%-1.7%4.370% 5/14/2024Boulder Hill Capital Management LP90,800$143K0.1%N/A0.037% Generate up to $5,000/month with 10X less money? (Ad)The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly income to cover housing, healthcare, food, and fun... With a fraction of what you probably think you need.Here's the secret to retiring without a million-dollar nest egg →5/3/2024 GSA Capital Partners LLP370,179$585K0.0%-27.2%0.150% 5/1/2024 Baillie Gifford & Co.15,871,875$25.08M0.0%-0.3%6.431% 4/19/2024 JTC Employer Solutions Trustee Ltd26,156$41K0.0%N/A0.003% 4/15/2024 Key Client Fiduciary Advisors LLC268,655$424K0.2%-20.2%0.027% 4/15/2024 Columbia Advisory Partners LLC15,585$25K0.0%N/A0.002% 3/5/2024 Twin Focus Capital Partners LLC55,526$44K0.0%N/A0.006% 1/26/2024 Baillie Gifford & Co.15,912,140$12.62M0.0%-7.2%1.600% 1/9/2024 Key Client Fiduciary Advisors LLC336,620$267K0.2%+6.4%0.034% 1/8/2024 Harbor Capital Advisors Inc.147,732$117K0.0%+9.9%0.015% 11/13/2023 Baillie Gifford & Co.17,147,409$13.38M0.0%-0.2%1.725% 10/27/2023 Marquette Asset Management LLC99,349$77K0.0%N/A0.010% 10/27/2023 Acuitas Investments LLC479,764$374K0.2%N/A0.048% 10/20/2023 Harbor Capital Advisors Inc.134,415$105K0.0%+19.5%0.014% 9/21/2023 Barclays PLC50,061$46K0.0%N/A0.005% 9/7/2023 MPM Asset Management LLC6,287,101$5.82M2.9%N/A0.632% 8/15/2023 Black Maple Capital Management LP69,839$65K0.0%N/A0.007% 8/14/2023 X Square Capital LLC26,771$25K0.0%N/A0.003% 8/14/2023 CSS LLC IL90,702$84K0.0%N/A0.009% 8/11/2023 Artal Group S.A.1,133,775$1.05M0.0%N/A0.114% 8/7/2023 Acadian Asset Management LLC358,010$329K0.0%+15.1%0.036% 8/3/2023 Oppenheimer & Co. Inc.68,171$63K0.0%N/A0.007% 7/28/2023 Baillie Gifford & Co.17,176,135$15.89M0.0%+0.4%1.728% 7/11/2023 Harbor Capital Advisors Inc.112,516$104K0.0%N/A0.073% 5/17/2023 Long Focus Capital Management LLC5,435,439$5.93M0.3%+2.9%3.514% 5/12/2023 Long Focus Capital Management LLC2,772,791$3.02M0.3%-47.5%1.793% 5/10/2023 Simplify Asset Management Inc.150,000$164K0.0%N/A0.097% 5/3/2023 Baillie Gifford & Co.17,112,002$18.65M0.0%-0.3%11.064% 5/1/2023 Virtu Financial LLC88,234$96K0.0%+193.1%0.057% 4/25/2023 Key Client Fiduciary Advisors LLC321,155$350K0.2%+8.2%0.208% 2/15/2023Endurant Capital Management LP1,733,236$2.53M1.0%-3.1%1.058% 2/14/2023 Susquehanna International Group LLP28,126$41K0.0%N/A0.017% 2/9/2023 HBK Sorce Advisory LLC70,000$65K0.0%+100.0%0.043% 1/17/2023 Key Client Fiduciary Advisors LLC296,740$433K0.3%-31.9%0.181% 1/11/2023 Vigilare Wealth Management28,800$42K0.0%-21.7%0.018% 11/15/2022 PFM Health Sciences LP9,320,584$10.02M0.4%+2.3%5.689% 11/15/2022 Long Focus Capital Management LLC4,789,490$5.15M0.5%+2.4%2.923% 11/15/2022Endurant Capital Management LP1,788,517$1.92M0.6%-1.9%1.092% 11/14/2022 HBK Sorce Advisory LLC35,000$32K0.0%N/A0.021% 11/10/2022 ExodusPoint Capital Management LP370,288$398K0.0%+23.4%0.227% 11/7/2022 Virtu Financial LLC40,503$44K0.0%+133.7%0.025% 11/3/2022 Barclays PLC340,068$366K0.0%+34.6%0.208% 10/27/2022 Baillie Gifford & Co.14,664,936$15.76M0.0%-4.3%8.977% 10/12/2022 Key Client Fiduciary Advisors LLC435,985$469K0.4%+4.8%0.267% 8/12/2022 Rafferty Asset Management LLC217,123$369K0.0%-59.5%0.134% 8/11/2022 Alps Advisors Inc.96,110$163K0.0%N/A0.059% 8/10/2022 Hunter Associates Investment Management LLC28,500$49K0.0%+42.5%0.018% 8/8/2022 Baillie Gifford & Co.15,321,346$26.05M0.0%-0.4%9.457% 7/11/2022 Vigilare Wealth Management41,800$71K0.1%N/A0.026% 5/17/2022Endurant Capital Management LP2,160,890$4.45M1.2%+140.7%1.335% 5/16/2022 Eversept Partners LP237,086$488K0.0%-32.0%0.151% Trump’s national nightmare is here (Ad)Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.Watch the National Emergency broadcast here5/11/2022 GSA Capital Partners LLP69,612$143K0.0%-17.3%0.044% 5/5/2022 Baillie Gifford & Co.15,380,538$31.68M0.0%+11.8%9.805% 5/5/2022Levy Wealth Management Group LLC17,590$36K0.0%N/A0.011% 4/29/2022 Daiwa Securities Group Inc.35,516$73K0.0%+44.9%0.023% 4/26/2022 Hunter Associates Investment Management LLC20,000$41K0.0%+81.8%0.013% 4/21/2022 Inspire Investing LLC31,928$66K0.0%+107.4%0.020% 4/21/2022 Inspire Advisors LLC45,105$93K0.0%+193.0%0.029% 4/18/2022 Key Client Fiduciary Advisors LLC420,447$866K0.7%+58.0%0.268% 2/14/2022 Long Focus Capital Management LLC2,162,313$8.11M1.1%N/A1.384% 2/14/2022 Point72 Asset Management L.P.565,208$2.12M0.0%+640.8%0.362% (Data available from 1/1/2016 forward) ADAP Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ADAP shares? During the previous two years, 35 institutional investors and hedge funds held shares of Adaptimmune Therapeutics. The most heavily invested institutionals were Matrix Capital Management Company LP ($35.81M), Baker BROS. Advisors LP ($17.04M), PFM Health Sciences LP ($9.51M), Baillie Gifford & Co. ($6.37M), Two Seas Capital LP ($5.41M), Long Focus Capital Management LLC ($4.68M), and FMR LLC ($1.66M).Learn more on Adaptimmune Therapeutics' institutional investors. What percentage of Adaptimmune Therapeutics' stock is owned by institutional investors? 31.37% of Adaptimmune Therapeutics' stock is owned by institutional investors. Learn more on ADAP's institutional investor holdings. Which institutional investors have been buying Adaptimmune Therapeutics' stock? Of the 27 institutional investors that purchased Adaptimmune Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Two Seas Capital LP ($37.42M), Long Focus Capital Management LLC ($12.12M), MPM Asset Management LLC ($6.29M), Acadian Asset Management LLC ($1.71M), Baillie Gifford & Co. ($1.63M), Renaissance Technologies LLC ($1.26M), and Empirical Finance LLC ($800K). How much institutional buying is happening at Adaptimmune Therapeutics? Institutional investors have bought a total of 53,646,230 shares in the last 24 months. This purchase volume represents approximately $25.21M in transactions. Which of Adaptimmune Therapeutics' major shareholders have been selling company stock? Of the 9 institutional investors that sold Adaptimmune Therapeutics' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Baillie Gifford & Co. ($4.96M), Bank of America Corp DE ($1.79M), Matrix Capital Management Company LP ($1.29M), MPM Asset Management LLC ($745.78K), MPM Bioimpact LLC ($684.09K), PFM Health Sciences LP ($519.44K), and JPMorgan Chase & Co. ($128.59K). How much institutional selling is happening at Adaptimmune Therapeutics? Institutional investors have sold a total of 10,318,875 shares in the last 24 months. This volume of shares sold represents approximately $5.79M in transactions. Related Companies GANX Major Shareholders CVM Major Shareholders HOWL Major Shareholders IZTC Major Shareholders ADVM Major Shareholders INKT Major Shareholders UNCY Major Shareholders DRRX Major Shareholders KALA Major Shareholders IFRX Major Shareholders This page (NASDAQ:ADAP) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access